Live Analyst Rating Changes 45986 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Daniel Brims
LS

Daniel Brims

Lake Street
Wall Street Analyst
★★☆☆☆
#2469
on 13Foresight · ranked by our own returns
38%
Success Rate
-12.3%
Average Return
5 of 13 calls profitable · +24.8% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 38% of Daniel Brims's ratings turned a profit when each position was held for 1 year — averaging -12.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

15 Buy 0 Hold 0 Sell
Daniel's Stock Coverage 10 ratings · 2026-10-24
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
RZLT
Rezolute
 Oct 06, 2026 BUY Strong Buy
+205.0% avg upside
14 analysts
$12.00
211.22% Upside
 -10.8% ·
VKTX
Viking Therapeutics
 Sep 23, 2026 BUY Strong Buy
+197.8% avg upside
31 analysts
$89.00
264.76% Upside
 -41.4% ·
KYNB
Kyntra Bio
 Sep 17, 2026 BUY Buy
+598.9% avg upside
17 analysts
$41.00
795.23% Upside
 -26.5% ·
SPRB
Spruce Biosciences
 Sep 17, 2026 BUY Strong Buy
+136.5% avg upside
16 analysts
$149.00
230.05% Upside
 -23.4% ·
KURA
Kura Oncology
 Sep 10, 2026 BUY Strong Buy
+171.3% avg upside
27 analysts
$23.00
139.35% Upside
 -14.0% ·
ALGS
Aligos Therapeutics
 Aug 07, 2026 BUY Strong Buy
+859.9% avg upside
11 analysts
$45.00
841.50% Upside
 -14.5% ·
RANI
Rani Therapeutics Holdings
 May 18, 2026 BUY Strong Buy
+1408.9% avg upside
10 analysts
$9.00
1385.30% Upside
 -34.1% ·
LITS
Lite Strategy
 Sep 02, 2015 BUY Strong Buy
+821.9% avg upside
13 analysts
$7.00
503.43% Upside
 · ·
IMNN
Imunon
 Aug 10, 2015 BUY Strong Buy
+1089.6% avg upside
11 analysts
$7.00
466.85% Upside
 · ·
TSE:BHC
Bausch Health Companies
 Dec 30, 2014 BUY Buy
+546.5% avg upside
29 analysts
 — · ·
🔒 5 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Daniel Brims — Frequently Asked Questions
How accurate are Daniel Brims's stock ratings?
Based on the calls 13Foresight could measure, about 38% of Daniel's ratings were profitable over a one-year hold, with an average return of -12.3% per rating, or +24.8% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Daniel ranked on 13Foresight?
Daniel Brims is currently ranked #2469 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Daniel cover?
Daniel most recently has ratings on RZLT, VKTX, KYNB, SPRB, KURA, ALGS, RANI, LITS, IMNN, TSE:BHC. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.